Daily Brief ECM: IPO Databook: Spectral Capital (FCCN US) – Aug 2026 and more

• Spectral Capital Corporation is a technology-focused holding company pursuing a growth strategy centered on acquiring, integrating, and advancing businesses in telecommunications, data infrastructure, and advanced computing technologies.
• Spectral Capital served approximately 335 enterprise customers as of March 31, 2026, with Q1 2026 revenue run rate approaching $1 billion annualized.
• Spectral Capital suffered recurring losses from operations and has a working capital deficit, raising substantial doubt about its ability to continue.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• BlossomHill upsized its IPO 20% but opened 1.6% below issue, suggesting the enlarged deal stretched underlying demand.
• BH-30643 remains the primary value driver, targeting resistant EGFR-mutant NSCLC, including the underserved C797S-positive population.
• The stock closed at its $16 IPO price, but persistent intraday weakness suggests investors may need patience as clinical catalysts develop.

• Latigo upsized its offering and priced at the high end, reflecting significant institutional demand entering the public markets.
• LTGO opened 16.7% above its IPO price but steadily sold off, closing just 1.4% above $18.00.
• Phase 3 catalyst ahead: LTG-001 is expected to enter Phase 3 development in 2H 2026, providing an important clinical catalyst and potential de-risking event.